R.R. Li

机构：AbbVie (United States)

发表论文 7 篇 · 总被引 38 次 · h-index 4

代表论文

• 1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study (2024 · Annals of Oncology · 被引 12)
• 1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study (2024 · Annals of Oncology · 被引 9)
• 691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors (2023 · Annals of Oncology · 被引 7)
• 2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC) (2025 · Annals of Oncology · 被引 4)
• 731MO Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase I study (2025 · Annals of Oncology · 被引 3)
• 918O Telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with MET-amplified (MET-amp) advanced solid tumors: Results from a phase I study (2025 · Annals of Oncology · 被引 3)